Plexus Corp (PLXS) · Nov 19, 2026 · Exec change

Plexus board change: Foate exits, Schrock to become chair

Chair succession — Schrock succeeds Foate after the 2027 annual meeting

Plexus announced a 2027 board-chair transition from Dean Foate to lead director Michael Schrock, alongside a smaller nine-member board.

Plexus is a global manufacturing partner focused on complex products in Aerospace/Defense, Healthcare/Life Sciences, and Industrial markets, with recent growth built around new program launches and market-share gains.

The transition is orderly, not an operating setback. Chair Dean Foate will leave the board after the 2027 annual meeting, while current lead director Michael Schrock is designated to succeed him; the filing explicitly says Foate’s decision is personal and not tied to any disagreement. 〔0〕

Continuity limits the business impact. Schrock is already a board member and lead director, so this is an internal handoff rather than a change in strategic control. The reduction from ten directors to nine is modest housekeeping, but it also removes an experienced chair from the board and makes shareholder reelection a condition of the succession. 〔1〕

Bottom line: This is a credible, low-disruption governance transition rather than a change to Plexus’s operating story. It matters mainly as a leadership handoff, with continuity outweighing the loss of the current chair.

What to watch next

2027 annual meeting and Schrock reelection

Original filing on SEC EDGAR

More Plexus Corp news

Plexus board change: Foate exits, Schrock to become chair | PLXS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.